Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$1.01M+31.01%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lindsay Androski
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 19
- Beta
- 0.62
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 31.97
Financials
Revenue
$1.01M+31.0%Net Income
$-5.14MEBITDA
$-5.11MFree Cash Flow
$-6.02MEPS (diluted)
$-0.03Shares Outstanding (diluted)
197.47M+268.1%Operating Expenses
$6.76MCash & Debt
$92.63MReturn of Capital
$0.00Revenue by Segment (annual)
$12.72MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $14.08M | $-33.50M | $-0.17 |
| 2024 | $6.17M | $-69.92M | $-0.38 |
| 2023 | $18.14M | $-72.85M | $-0.44 |
| 2022 | $39.02M | $-69.46M | $-0.46 |
| 2021 | $10.99M | $-76.25M | $-0.73 |
| 2020 | $6.91M | $-63.74M | $-0.86 |
| 2019 | $6.01M | $-153.72M | $-2.69 |
| 2018 | $5.90M | $-57.10M | $-1.03 |
| 2017 | $10.70M | $-84.40M | $-1.54 |
| 2016 | $1.50M | $-384.10M | $-7.24 |
| 2015 | $24.87M | $-61.12M | $-1.34 |
| 2014 | $15.00M | $-38.80M | $-1.80 |
| 2013 | $15.46M | $-14.06M | $-0.92 |
| 2012 | $14.18M | $29.95M | $2.16 |
Valuation
ABUShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-33.33%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·5d ago·Negative
…s Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the final results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded by way of a modified Dutch auction, whic…
View source ↗ - Newsglobenewswire.com·6d ago·Negative
…minary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the preliminary results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded by way of a modified Dutch auction…
View source ↗ - Newsglobenewswire.com·43d ago·Neutral
… Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”) at a price of not less than US$5.00 and not more than…
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
… Million of its Common Shares Through Modified “Dutch Auction” Tender Offer WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified “Dutch Auction” tender offer (the “Offer”) to repurchase up to US$230 million of its common shares at a purchase price of not less than US$5.00 per share and not more than US$5.75…
View source ↗ - Newsglobenewswire.com·55d ago·Positive
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026
View source ↗
Earnings
Mon, Nov 16(in 6 weeks)
Consensus estimate $-0.02 per share
Typical surprise +28.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.03 vs $-0.02miss
- Wed, May 13$0.87 vs $-0.03beat
- Mon, Mar 23$-0.01 vs $-0.04beat
- Thu, Nov 13$-0.04 vs $-0.06beat
- Wed, Aug 6$0.01 vs $-0.02beat
- Wed, May 14$-0.13 vs $-0.09miss
Estimates and results for ABUS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ABUS officers and directors.
- Bought
- —
- Sold
- $363k
0 trades
9 trades
- Hastings David Csold
- Sims Karensold
- Mcelhaugh Michael J.sold
- Naftzger J. Christophersold
- Manchester Keith Ssold
- Sims Karensold
- Hastings David Csold
- Sofia Michael J.sold
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ABUS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.